Actinic keratosis prevention - A double-blind, half-face interventional study with a topical treatment

Abstract

Actinic keratosis (AK) is a chronic and recurrent disease and in this double-blind, half face, placebo controlled study we attempt to examine the efficacy of a topical treatment containing 2,4,6-octatrienoic acid and anthraquinone knipholone for the prevention of new AK lesion formations. New lesion onset was detected with methyl-5-aminolevulinic acid and Wood’s lamp after 6 months of treatment (T1) and 12 months after treatment end (T2). Absence of new lesion at T1, was 86.11% in active treatment side while 77.78% in placebo side. At T2 the percentage was higher in skin treated with active product (83.33% of subjects) compared to placebo (63.89% of subjects). Taking into consideration the number of new lesions during the study period, at T1 the new AK lesions were not statistically significantly influenced by the treatments, while at T2, AK lesions were detected in 30.55% of placebo-treated area while in the contralateral part the lesions were 13.89%. The reduction induced by active treatment was statistically significant. The product containing 2,4,6-octatrienoicienoic acid and anthraquinone knipholone is effective in reducing new AK lesion formation in subjects with a history of AKs.

Keywords

Actinic keratosis prevention / Actinic keratosis lesion onset / 2,4,6-octatrienoic acid / Anthraquinone knipholone

References

[1] Bickers DR, Lim HW, Margolis D, et al. American Academy of Dermatology Association; Society for Investigative Dermatology. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investiga-tive Dermatology. J Am Acad Dermatol. 2006 Sep; 55(3): 490-500. https://doi.org/10.1016/j.jaad.2006.05.048

[2] Casari A, Chester J, Pellacani G. Actinic Keratosis and Non-Invasive Diagnostic Techniques: An Update. Biomedicines. 2018; 6(1): E8. https://doi.org/10.3390/biomedicines6010008

[3] Jetter N, Chandan N, Wang S, et al. Field Cancerization Therapies for Management of Actinic Keratosis: A Narrative Review. Am J Clin Dermatol. 2018 Mar; 26. https://doi.org/10.1007/s40257-018-0348-7

[4] Siegel JA, Korgavkar K, Weinstock MA. Current perspective on ac-tinic keratosis: A review. Br J Dermatol. 2017 Aug; 177(2): 350-358. https://doi.org/10.1111/bjd.14852

[5] Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000 Jan; 42(1): 4-7. https://doi.org/10.1067/mjd.2000.103342

[6] Rosen T, Lebwohl MG. Prevalence and awareness of actinic kerato-sis: barriers and opportunities. J Am Acad Dermatol. 2013 Jan; 68(1Suppl 1): S2-9. https://doi.org/10.1016/j.jaad.2012.09.052

[7] Peris K, Calzavara-Pinton PG, Neri L, et al. Italian expert consen-sus for the management of actinic keratosis in immunocompetent patients. J Eur Acad Dermatol Venereol. 2016 Jul; 30(7): 1077-84. https://doi.org/10.1111/jdv.13648

[8] Dodds A, Chia A, Shumack S. Actinic keratosis: rationale and management. Dermatol Ther (Heidelb). 2014 Jun; 4(1): 11-31. https://doi.org/10.1007/s13555-014-0049-y

[9] Naldi L, Chatenoud L, Piccitto R, et al. Prevalence of Actinic Ker-atoses Italian Study (PraKtis) Group. Prevalence of actinic keratoses and associated factors in a representative sample of the Italian adult population: Results from the Prevalence of Actinic Keratoses Ital-ian Study, 2003-2004. Arch Dermatol. 2006 Jun; 142(6): 722-6. https://doi.org/10.1001/archderm.142.6.722

[10] Fargnoli MC, Altomare G, Benati E, et al. Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics. Eur J Dermatol. 2017 Dec; 27(6): 599-608.

[11] Berman B, Cockerell CJ. Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation. J Am Acad Der-matol. 2013 Jan; 68(1Suppl 1): S10-9. https://doi.org/10.1016/j.jaad.2012.09.053

[12] Kennedy C, Bajdik CD, Willemze R, et al. Leiden Skin Cancer Study. The influence of painful sunburns and lifetime sun exposure on the risk of actinic keratoses, seborrheic warts, melanocytic nevi, atypical nevi, and skin cancer. J Invest Dermatol. 2003 Jun; 120(6): 1087-93. https://doi.org/10.1046/j.1523-1747.2003.12246.x

[13] Traianou A, Ulrich M, Apalla Z, et al. Risk factors for actinic kerato-sis in eight European centres: a case-control study. Br J Dermatol. 2012 Aug; 167(Suppl 2): 36-42. https://doi.org/10.1111/j.1365-2133.2012.11085.x

[14] Krutmann J, Berking C, Berneburg M, et al. New Strategies in the Prevention of Actinic Keratosis: A Critical Review. Skin Pharmacol Physiol. 2015; 28(6): 281-9. https://doi.org/10.1159/000437272

[15] Emmert S, Schön MP, Haenssle HA. Molecular biology of basal and squamous cell carcinomas. Adv Exp Med Biol. 2014; 810: 234-52. https://doi.org/10.1007/978-1-4939-0437-2_13

[16] Werner RN, Sammain A, Erdmann R, et al. The natural history of actinic keratosis: A systematic review. Br J Dermatol. 2013 Sep; 169(3): 502-18. https://doi.org/10.1111/bjd.12420

[17] Malvehy J. A new vision of actinic keratosis beyond visible clinical lesions. J Eur Acad Dermatol Venereol. 2015 Jan; 29(Suppl 1): 3-8. https://doi.org/10.1111/jdv.12833

[18] Torezan LA, Festa-Neto C. Cutaneous field cancerization: Clini-cal, histopathological and therapeutic aspects. An Bras Dermatol. 2013 Sep-Oct; 88(5): 775-86. https://doi.org/10.1590/abd1806-4841.20132300

[19] Cubeddu R, Pifferi A, Taroni P, et al. Fluorescence Lifetime Imaging: An Application to the Detection of Skin Tumors IEEE. Journal of Selected Topics in Quantum Electronics. 1999 Jul/Aug; 5(4): 923-29.

[20] Sanmartin O, Guillen C. Images in clinical medicine. Fluorescence diagnosis of subclinical actinic keratoses. N Engl J Med. 2008 May; 358(19): e21. https://doi.org/10.1056/NEJMicm071130

[21] Briganti S, Flori E, Bellei B, et al. Modulation of PPAR provides new insights in a stress induced premature senescence model. PLoS One. 2014 Aug; 9(8): e104045. https://doi.org/10.1371/journal.pone.0104045

[22] Wube AA, Bucar F, Asres K, et al. A selective inhibitor of leukotriene metabolism. Phytomedicine. 2006 Jun; 13(6): 452-6. https://doi.org/10.1016/j.phymed.2005.01.012

[23] Glogau RG. Aesthetic and anatomic analysis of the aging skin. Semin Cutan Med Surg. 1996 Sep; 15(3): 134-8.

[24] Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007 Dec; 157(Suppl 2): 34-40. https://doi.org/10.1111/j.1365-2133.2007.08271.x

[25] Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled tri-als. J Am Acad Dermatol. 2004 May; 50(5): 714-21. https://doi.org/10.1016/j.jaad.2003.12.010

[26] Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012 Mar; 366(11): 1010-9. https://doi.org/10.1056/NEJMoa1111170

[27] Ulrich M, Lange-Asschenfeldt S, Rowert-Huber J. Effects of ingenol mebutate 0.05% gel for the treatment of actinic field cancerization including subclinical actinic keratoses - assessment by reflectance confocal microscopy. Br J Dermatol. 2014; 171(Suppl 4): 1-76.

[28] Cantisani C, De Gado F, Ulrich M, et al. Actinic keratosis: Review of the literature and new patents. Recent Pat Inflamm Allergy Drug Discov. 2013 May; 7(2): 168-75. https://doi.org/10.2174/1872213X11307020008

[29] Ulrich M, Alarcon I, Malvehy J, et al. In vivo reflectance confocal microscopy characterization of field-directed 5-fluorouracil 0.5%/sali-cylic acid 10% in actinic keratosis. Dermatology. 2015; 230: 193-198. https://doi.org/10.1159/000370148

[30] Cantisani C, Paolino G, Corsetti P, et al. Evaluation of Ingenol mebu-tate efficacy for the treatment of actinic keratosis with Antera 3D camera. Eur Rev Med Pharmacol Sci. 2015; 19: 92-97.

[31] Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med. 1993 Oct; 329(16): 1147-51. https://doi.org/10.1056/NEJM199310143291602

[32] Darlington S, Williams G, Neale R, et al. A randomized controlled trial to assess sunscreen application and beta carotene supplementa-tion in the prevention of solar keratoses. Arch Dermatol. 2003 Apr; 139(4): 451-5. https://doi.org/10.1001/archderm.139.4.451

[33] Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet. 1999 Aug; 354(9180):723-9. Erratum in: Lancet 1999 Sep 18; 354(9183): 1038. https://doi.org/10.1016/S0140-6736(98)12168-2

[34] Elmets CA, Viner JL, Pentland AP, et al. Chemoprevention of non-melanoma skin cancer with celecoxib: A randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2010 Dec; 102(24): 1835-44. https://doi.org/10.1093/jnci/djq442

[35] Dréno B, Amici JM, Basset-Seguin N, et al. Management of ac-tinic keratosis: A practical report and treatment algorithm from AKTeamTM expert clinicians. J Eur Acad Dermatol Venereol. 2014 Sep; 28(9): 1141-9. https://doi.org/10.1111/jdv.12434

[36] Neale R, Williams G, Green A. Application patterns among partici-pants randomized to daily sunscreen use in a skin cancer prevention trial. Arch Dermatol. 2002 Oct; 138(10): 1319-25.

[37] Dirschka T, Gupta G, Micali G, et al. Real-world approach to ac-tinic keratosis management: Practical treatment algorithm for office-based dermatology. J Dermatolog Treat. 2017 Aug; 28(5): 431-442. https://doi.org/10.1080/09546634.2016.1254328

[38] Flori E, Mastrofrancesco A, Kovacs D, et al. The activation of PPAR by 2,4,6-Octatrienoic acid protects human keratinocytes from UVR-induced damages. Sci Rep. 2017 Aug; 7(1): 9241. https://doi.org/10.1038/s41598-017-09578-3